Next Generation Eye Care

Transcription

1 Next Generation Eye Care

2 Company Overview Ocular Science is an innovative biotech and pharmaceutical company that offers paradigm-shifting eye care products to physicians and their patients in a cost-effective manner. Our transformative technologies center around surgical vision correction for patients with cataracts and LASIK as well as the management of dry eye, glaucoma and retina disease.

3 Our Team Anthony Sampietro CEO, Founder Damien Goldberg, M.D. CMO, Founder Amy Frost CPO Charlie Hicks CFO Mark Puwal VP, Sales

4 Problem Drug prices are skyrocketing, insurance coverage is decreasing and there is a glaring lack of quality, affordable pharmaceutical options on the ophthalmic market.

5 Solution Ocular Science is well-positioned to solve these industry challenges and capitalize on the growing demands of the blended patient payment market through a portfolio of innovative ophthalmology products, which are user-friendly, efficacious and affordable. The Ocular Science product lineup creates the ability to not just succeed, but revolutionize the entire eye care patient experience.

6 Traction The domestic revenue opportunity for these markets, at Ocular Science ASPs, totals $223.96B annually. Capturing a very conservative.079% of the market will generate $177 MM in revenue and $48 MM in EBITDA over the next five years. Ocular Science is posting 246% YTD growth with no signs of slowing and boasts four distinct competitive advantages that are fueling market share and growth: Unrivaled collection of products for the surgical vision correction and glaucoma markets Groundbreaking biologics for managing dry eye disease Medical Advisory Board featuring 29 of the world s key opinion leaders in ophthalmology Executive team with more than 75 years of combined experience in surgical and pharmaceutical industries

7 Market CATARACT GLAUCOMA PRESBYOPIA LASIK DRY EYE Total Procedures 3.8 Million Revenue $323 Million Total Patients 3 Million Revenue $1.62 Billion Total Patients 110 Million Revenue $132 Billion Total Procedures 600,000 Revenue $18 Million Total Patients 30 Million Revenue $90 Billion OPPORTUNITY Total Revenue Opportunity $ Billion Annually Ocular Science Capture of.079% of the Market Ocular Science Revenue $177 Million (5 years) Ocular Science EBITDA $48 Million (5 years)

8 Competition Ocular Science has only two significant competitors in the compounded medication and biologic spaces Imprimis (compounds) and Bio-Tissue (biologics). OCULAR SCIENCE DIFFERENTIATORS: Ocular Science produces high-quality compounded medications at a lower cost Ocular Science offers Genesis, an effective amniotic cytokine extract for managing dry eye disease Ocular Science has two potentially eye care industry-altering products in the pipeline

9 Product Pipeline EyeFocus Drop that corrects presbyopia, the gradual loss of near vision Renaissance Biologic drop that improves dry eye symptoms in two to four weeks

10 Economics Ocular Science s margin is 57% on its combined product lines. Month-over-month revenue growth is currently 13 percent and will continue to increase. The Growth Case projects 8.4% month-overmonth growth for the next five years propelled by a $6 MM Series A capital raise. During this period, Ocular Science will: Assemble world-class sales & marketing team Expand existing 503A compounding pharmacy Build an additional 503A facility, two 503B compounding pharmacies, two tissue banks and an R&D facility

11 Commercial & Operational Expansion Plan Launch 2017 Growth Growth Growth Products $695,934 in Revenue 503A Pharmacy Complete 1 Vice President of Sales 1 Key Account Executive 15 Products $13.6 MM in Revenue $1.2 MM in EBITDA 503A Pharmacy Expansion Complete 503B Pharmacy Complete Tissue Bank Complete 6 Account Executives 1 Marketing Director 1 Product Manager 1 Director of HR 8 Clinical Studies 19 Products $76.5 MM in Revenue $16.7 MM in EBITDA 2 nd 503A Pharmacy Complete 2 nd 503B Pharmacy Complete 2 nd Tissue Bank Complete 15 Account Executives 3 Sales Managers 2 Product Managers 23 Products $87.8 MM in Revenue $40.9 MM in EBITDA R&D Facility Complete 6 Account Executives 1 Product Manager

12 The Ask